Liandan Powder Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is supplied as a multi-route active pharmaceutical ingredient powder for further manufacturing by GMP-licensed veterinary medicinal product facilities. No separate model codes are assigned to the individual dosage routes; the grade is identified by the full label phrase and the batch-specific certificate of analysis. The release specification is structured around five control domains: identity and assay by liquid chromatography with reference standard per USP <621>, related substances by gradient liquid chromatography per Ph. Eur. 2.2.29, residual solvents by headspace gas chromatography per USP <467>, elemental impurities by ICP-MS per USP <232> and USP <233>, and physical micromeritics by laser diffraction according to ISO 13320:2020. The powder is not a final dosage form and is not intended for direct administration to animals without formulation, dilution, or terminal processing. Its primary operational difference from single-route API powders is that the particle-size envelope, flow behaviour, and low-bioburden profile determined by USP <61> are specified so that one bulk material can be transferred across solid oral, premix, solution, and injectable manufacturing operations.

What Differentiates a Multi-Dosage-Form Veterinary API Powder from Single-Route Grades?

Single-route API powders are usually micronized for suspension injectables, spray-dried for direct compression, or coarsely milled for premix. A multi-dosage-form powder cannot optimize one route at the expense of another; the physical specification is therefore set as an overlapping window rather than a sharp optimum. For solid oral manufacture, the powder is generally expected to exhibit a Hausner ratio below 1.25 and a Carr's index below 25% so that die fill on a rotary tablet press remains consistent; these values follow the flow classifications in USP <1174>. For injectable solutions, the powder must dissolve within a defined volume of water for injection at a specified temperature, and the resulting solution is filtered through a 0.22 µm sterilizing-grade membrane. These two requirements are not automatically compatible; over-milling improves dissolution but reduces flow and increases dusting. Liandan Powder therefore occupies a mid-range particle-size distribution rather than a monomodal ultrafine distribution. Published data for this specific product configuration are limited for all seven dosage routes; formulation-site development reports are required to confirm that the selected process remains within the registered release envelope.

Lot release for the powder includes assay and related substances by stability-indicating liquid chromatography, residual solvents by headspace gas chromatography, water content by Karl Fischer titration per USP <921>, sulfated ash, and elemental impurities by ICP-MS. Residual solvent acceptance follows ICH Q3C / VICH GL18; class 1 solvents are specified as absent, and class 2 solvents are controlled to concentration limits corresponding to the permitted daily exposure. Elemental impurities are controlled under ICH Q3D / VICH GL30 with confirmation by USP <233>. Water content is not listed as a single universal limit; it is recorded on the certificate of analysis because hydrolysis, hydration, or polymorphic conversion may affect blend uniformity and dissolution behaviour. The powder should be released with a loss on drying value consistent with the validated manufacturing process; moisture uptake above the validated limit during storage can change flow and compressibility even when assay and related substances remain acceptable.

Granulometric and Compression Performance Parameters

Powder behaviour during solid oral manufacture is controlled through particle-size distribution, bulk and tapped density, and flow function. Laser diffraction per ISO 13320:2020 is used with dry dispersion at 0.5 bar, 1.5 bar, and 3.0 bar to check dispersion sensitivity; the D10, D50, and D90 values are reported on each certificate of analysis. Direct compression formulations typically require a D50 in the 50–150 µm range and limited sub-10 µm fines; lot-specific D50 and span are used to determine whether additional milling or classification is necessary. Bulk density and tapped density are determined per USP <616> using a 100-mL cylinder and 1000 taps. From these values, the Hausner ratio and Carr's index are calculated. A Hausner ratio greater than 1.35 usually indicates that the powder will require granulation or pre-compaction before high-speed tableting. On a production-scale rotary tablet press running at 40–80 rpm with a force feeder, low-density powder can flood the die or cause variation in fill depth. Capsule filling on intermittent-motion dosing-disk machines is similarly sensitive to bulk density; powders outside the bulk-density range validated for the specific machine may require reduced tamping depth to avoid weight variation. These operational limits are not product-specific release criteria; they are process-transfer thresholds that should be evaluated with each machine train.

For medicated premix production, the powder is added by geometric dilution to a feed carrier in a horizontal ribbon mixer or twin-shaft paddle mixer. Blend uniformity is evaluated by sampling at 10 locations, with assay acceptance limits set in the marketing authorization. The powder should not segregate after blending; segregation tendency is inferred from particle-size span and bulk density. If span exceeds 2.5, the risk of fines migration during transport increases, requiring a granulation step or carrier particle-size adjustment. For solution preparations, solubility and pH are determined in water and in the proposed solvent system. A pH solubility profile is generated at 25 °C and 37 °C in buffers of known ionic strength; the data determine whether the API should be dissolved as a salt or as the free form. The dissolution operation is carried out in closed stainless-steel vessels equipped with a top-entering agitator; if the API is sensitive to alkaline pH, the solution is buffered to the registered pH range and protected from atmospheric carbon dioxide by nitrogen overlay. Clarification is performed through a 0.45 µm filter, followed by a 0.22 µm sterilizing-grade filter when the finished product is required to be sterile.

If Injectable-Grade Processing Requires Terminal Sterilization, What Material Attributes Change?

Use of the same powder in injectable formulations does not change the API identity, but it expands the release and process-control envelope. Injectable grades require a defined bacterial endotoxin limit measured by limulus amebocyte lysate per USP <85>; the limit is calculated from the maximum intended dose and the endotoxin limit of the finished injection, typically as EU/mg of API. If the product monograph does not assign a limit, the batch certificate should report the measured endotoxin concentration and the calculation basis. Sterility of the finished injection is confirmed by membrane filtration per USP <71> after 14 days incubation; the powder itself is not claimed to be sterile unless it has been specifically sterilized and released as such. Particulate matter in the finished injection is controlled by light obscuration per USP <788>; clear solutions prepared from the powder may require filtration through a 0.22 µm membrane to meet the subvisible particle counts for large-volume or small-volume parenterals. If terminal moist-heat sterilization is used, a cycle of 121 °C for 15 min may be evaluated only when forced degradation and thermal stability data show no unacceptable related-substance increase under these conditions. Dry-heat depyrogenation of contact equipment at 250 °C for 30 min is used when the equipment must be pyrogen-free but the API powder itself is not subjected to that temperature. Aqueous solution preparation should avoid strong oxidizing agents and avoid prolonged holding times above the validated temperature range, because both can accelerate degradation and raise related-substance levels.

Stability testing follows VICH GL3 and VICH GL5 for photostability, long-term, intermediate, and accelerated conditions. Packaging is selected to maintain moisture and light protection. A typical bulk container for APIs is a double low-density polyethylene liner inside a high-density polyethylene drum, with a polyester/aluminium/polyethylene laminate option for oxygen-sensitive material. At relative humidity above 60%, pre-drying or controlled-environment handling may be required before compression or capsule filling if water content increases beyond the validated limit. The powder should not be stored in unlined kraft or metal containers due to unidentified extractables risk. Manufacturers transferring the powder to aluminium or glass primary contact surfaces should perform a container-closure compatibility study under accelerated conditions to rule out migration of extractables into the formulation.

Table 1 summarizes route-specific critical material attributes and the corresponding compendial test methods.

Process transfer and equipment qualification require attention to three failure modes observed in multi-route manufacturing: fines migration during pneumatic transfer, moisture ingress during open-charge operations, and cross-contamination during changeover between species-specific formulations. Pneumatic transfer systems with high-velocity dense-phase conveying can generate fines and alter the particle-size distribution after the API has been released against its certificate of analysis; if the receiving bin is sampled after transfer, the D10 or D90 may shift. This is a process-induced change, not a raw material quality issue. Moisture ingress during open-charge operations at relative humidity above 60% can increase water content and reduce flow; use of split-valve containment valves or nitrogen-purged hoppers is preferable. Cleaning validation for multi-route veterinary products should follow residue limits derived from the most sensitive species and route, using swab sampling and HPLC per USP <621>.

Compared with a conventional single-route API powder, the multi-route grade reduces the number of inventory items but shifts the burden of route-specific optimization to the formulation site. A single-route powder for injectable suspension may be micronized to a D90 below 10 µm; that particle size can impair flow and increase dusting in a tablet blend. A single-route powder for direct compression may have acceptable flow but may be too coarse for suspension syringeability or solution clarity. The multi-route powder adopts an intermediate distribution and therefore may require additional dissolution testing, filter validation, or granulation optimization before a given route is locked. This is not a release failure; it is an inherent boundary condition of consolidated-grade supply. Applicants should compare the batch certificate against the specific process qualification ranges rather than assume that one powder performs identically on every machine.